Thyroid eye disease can cause eye bulging, double vision, and pain that make travel to infusion centers hard. In October 2026 the FDA approved Enspryng (satralizumab) as a subcutaneous, at-home option and the first interleukin-6 receptor inhibitor cleared for this indication.
How the SatraGO studies were built
Approval rested on SatraGO-1 and SatraGO-2, identically designed phase 3 trials in adults with active moderate-to-severe or chronic thyroid eye disease. Across 19 countries, 258 patients were randomized 1:1 to Enspryng or placebo. The primary endpoint was at least a 2 mm reduction in proptosis at week 24 in the study eye for active disease.
Results in brief
- SatraGO-1 did not meet its pre-specified primary endpoint at week 24.
- SatraGO-2 showed a significant proptosis response: 52.9% with Enspryng versus 23.4% with placebo.
- In SatraGO-2, diplopia improved in 60.7% versus 25.8% with placebo in the active population.
- Trial investigators noted treatment effects looked consistent across studies, with placebo response rates differing.
Experts quoted by Ophthalmology Times said proptosis improvement may be smaller than with some IGF-1 receptor antagonists, but the safety profile and home injections may help patients with other medical problems or limited access to infusion sites. Monitoring for medication risks remains essential.
How this differs from infusion drugs
Prior thyroid eye disease medicines often required infusion-center visits. A subcutaneous IL-6 receptor option may reduce travel burden, especially when double vision makes driving hard. It does not remove the need for orbital examination, thyroid control, and monitoring for drug-class risks. Choice among IGF-1 receptor antagonists, IL-6 blockade, steroids, or surgery belongs with an experienced thyroid-eye team.
Neutral education, not a sales pitch
Khanna Vision Institute does not treat complex orbital inflammatory disease as a primary surgical service. We educate patients, examine the ocular surface and optic nerve when thyroid eye disease is suspected, and refer to oculoplastics or thyroid-eye specialists for medical therapy decisions, including whether an IL-6 or IGF-1 pathway drug is appropriate.
- Report new double vision, eye bulging, or color vision change promptly.
- Bring thyroid laboratory results and a full medication list to visits.
- Ask who will monitor labs and orbital status if an at-home biologic is prescribed.
For more coastal eye-health articles while you wait for specialty appointments, see malibulasik.com.
Source: FDA approves subcutaneous Enspryng for TED (Ophthalmology Times, 10/16/2026). This article is an educational summary written by Khanna Vision Institute and is not a substitute for medical advice.